A consensus statement endorsing high-frequency (10 kHz) spinal cord stimulation (SCS) for refractory PDN has been released by Nevro Corp. This announcement was advised by experts in diabetes, pain in diabetic neuropathy, and health services from the Worldwide Initiative for Diabetes Education.
Experts Confirm High-frequency Scs, Especially Nevro’s Hfx, As Effective For Refractory Diabetic Neuropathy Pain
The effectiveness of high-frequency SCS in treating Pain in Diabetic Neuropathy PDN symptoms that do not improve with initial treatment is highlighted in the consensus statement published in Diabetes Research and Clinical Practice. The consensus declaration was created by an international multidisciplinary panel during the December 2022 World Wide Diabetes Virtual Global Summit. For PDN symptoms that are unresponsive to first- and second-line treatments, high-frequency SCS therapy is advised. These suggestions highlight the necessity of using SCS therapy—more especially, Nevro’s HFX for PDN—to treat PDN symptoms that are resistant to treatment.
Chief Medical Officer of Nevro, Dr. David Caraway, emphasized the importance of results from the largest RCT assessing SCS for PDN, the SENZA-PDN RCT, in confirming high-frequency (10 kHz) SCS for this patient group. The SENZA-PDN experiment has demonstrated the efficacy of high-frequency SCS in addressing challenging pain symptoms associated with diabetic neuropathy.
Lead primary investigator for SENZA-PDN and professor of neurosurgery, Dr. Erika Petersen, observed that throughout the trial, high-frequency SCS enhanced neurological function, sleep, quality of life, and pain relief. Her research indicates that PDN outcomes could be enhanced by high-frequency SCS.
Nevro’s 10 kHz Therapy™ is recognized globally for effectively relieving pain in diabetic neuropathy (PDN)
Diabetic neuropathy pain PDN can reduce quality of life and affect roughly 50% of people with type 2 diabetes. Oral pain relievers that are based on tradition may not work well or have unacceptably bad side effects. PDN sufferers thus have additional issues such as anxiety, depression, and sleep disruptions, as well as a worse quality of life in terms of their health.
Nevro’s 10 kHz TherapyTM is the only high-frequency paresthesia-free SCS system that has received FDA approval for treating pain in diabetic neuropathy PDN. The consensus statement attests to Nevro’s innovative technology’s ability to reduce pain and restore neurological function in individuals with diabetic neuropathic pain. The endorsement from internationally renowned specialists confirms Nevro’s commitment to creating remedies for persistent pain.
The American Diabetes Association, German Diabetes Association, and American Association of Clinical Endocrinologists support high-frequency SCS for Pain in Diabetic Neuropathy PDN treatment in addition to the consensus statement.